THEaddition of one year of treatment with thedurvalumab immunotherapy to standard maintenance therapy has reduced the risk of relapse by 32%. in patients with non-muscle invasive bladder cancer at high riskcompared to treatment with BCG alone.
These are the results of the phase III Potomac study presented at the 2025 congress of the European Society for Medical Oncology (Esmo) and simultaneously published on The Lancet. The standard treatment for these patients, explains Lorenzo Antonuzzo, director of Medical Oncology at Careggi University of Florence, “involves the use of BCG therapy after resection of the neoplasm.
The goal is reduce the risk of recurrence but a high percentage of relapses still occur, hence theneed for new treatment options. The results of the Potomac study demonstrate that the new regimen allows more patients to stay free from disease after two years“. (Images by Manuela Correra)
iO Donna © ALL RIGHTS RESERVED